Cleveland Diagnostics gets FDA breakthrough device status for prostate cancer diagnostic test
The data from multicentre prospective clinical trials demonstrated that the non-invasive, blood-based IsoPSA assay has significant superior diagnostic accuracy compared to traditional prostate-specific antigen (PSA) tests in detecting